Taniborbactam

A beta-lactamase inhibitor used in combination with antibiotics

Taniborbactam is a novel beta-lactamase inhibitor that is used in combination with antibiotics to combat antibiotic resistance. It is particularly effective against carbapenem-resistant Enterobacteriaceae (CRE), which are a significant concern in healthcare settings due to their resistance to many conventional antibiotics.

Mechanism of Action

Taniborbactam works by inhibiting the activity of beta-lactamase enzymes produced by certain bacteria. These enzymes are responsible for breaking down beta-lactam antibiotics, rendering them ineffective. By inhibiting these enzymes, taniborbactam restores the efficacy of beta-lactam antibiotics against resistant bacterial strains.

Chemical Structure

Chemical structure of Taniborbactam

Taniborbactam is a boronic acid-based inhibitor, which distinguishes it from other classes of beta-lactamase inhibitors. Its unique structure allows it to bind effectively to a wide range of beta-lactamase enzymes, including both serine and metallo-beta-lactamases.

Clinical Use

Taniborbactam is typically used in combination with cefepime, a fourth-generation cephalosporin antibiotic. This combination has shown promise in treating infections caused by multi-drug resistant organisms, particularly those producing carbapenemases such as Klebsiella pneumoniae carbapenemase (KPC) and New Delhi metallo-beta-lactamase (NDM).

Development and Approval

Taniborbactam is currently undergoing clinical trials to assess its safety and efficacy in humans. It represents a significant advancement in the fight against antibiotic-resistant infections, offering a potential new treatment option for infections that are difficult to treat with existing antibiotics.

Related Pages

• Antibiotic resistance
• Beta-lactamase
• Carbapenem-resistant Enterobacteriaceae
• Cefepime